Tag - EYPT

Developments

EyePoint to sell YUTIQ to Alimera Sciences for $82.5-million

EyePoint Pharmaceuticals (NASDAQ:EYPT) entered into a definitive agreement for the sale of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences (NASDAQ:ALIM). Under the accord, EyePoint...

May 18, 2023

Feature

EyePoint focused on long-lasting treatments for wet AMD and DR

EyePoint Pharmaceuticals (NASDAQ:EYPT) is advancing its lead drug candidate, EYP-1901, in two Phase 2 clinical trials as a potential six-month treatment for wet age-related macular degeneration (AMD) and a potential...

April 25, 2023

Developments

EyePoint completes enrollment in Phase 2 wet AMD trial

EyePoint Pharmaceuticals (NASDAQ:EYPT) completed enrollment in the Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial evaluating EYP-1901 as a potential six-month maintenance...

March 27, 2023

Developments

EyePoint presents YUTIQ 36-month follow up Phase 3 data at ARVO

EyePoint Pharmaceuticals (NASDAQ:EYPT) presented 36-month efficacy and safety data supporting its YUTIQ three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the...

May 1, 2019

Developments

EyePoint Pharma launches DEXYCU intraocular suspension in U.S.

EyePoint Pharmaceuticals (NASDAQ:EYPT) commercially launched DEXYCU in the U.S. as the first and only FDA-approved intraocular steroid for the treatment of postoperative inflammation. DEXYCU is administered as a single...

March 13, 2019

Tag - EYPT

EyePoint to sell YUTIQ to Alimera Sciences for $82.5-million

EyePoint focused on long-lasting treatments for wet AMD and DR

EyePoint completes enrollment in Phase 2 wet AMD trial

EyePoint presents YUTIQ 36-month follow up Phase 3 data at ARVO

EyePoint Pharma launches DEXYCU intraocular suspension in U.S.

General

More